Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
JAMA|March 4, 2008
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett, Samuel M Silver, Benjamin Djulbegovic, et al.Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.The New England Journal of Medicine|June 3, 2011
gp100 peptide vaccine and interleukin-2 in patients with advanced melanomaDouglas J Schwartzentruber, David H Lawson, Jon M Richards, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.Genome Biology|May 10, 2022
Refining colorectal cancer classification and clinical stratification through a single-cell atlasAteeq M Khaliq, Cihat Erdogan, Zeyneb Kurt, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Bladder cancerPeter E Clark, Neeraj Agarwal, Matthew C Biagioli, et al.Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Testicular Cancer, Version 2.2015Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.Pageof 12